Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease
- PMID: 14976595
- DOI: 10.1086/381982
Low antibody levels against cell wall-attached proteins of Streptococcus pyogenes predispose for severe invasive disease
Abstract
Acute-phase serum samples from 70 patients with group A streptococcal (GAS) invasive disease were analyzed for IgG antibodies against 6 recently characterized GAS virulence factors (SclA, SclB, GRAB, MtsA, EndoS, and IdeS) and SpeB. Antibody levels against the cell wall-attached GAS antigens SclA, SclB, and GRAB were significantly lower in patients with severe invasive disease (streptococcal toxic shock syndrome [STSS] and/or necrotizing fasciitis [NF]; n=35), compared with levels in patients with nonsevere GAS bacteremia (n=35). Among patients with severe invasive disease, significantly lower antibody levels against GRAB were found in patients with STSS (n=10) than in patients with NF (n=17). Antibody levels against SpeB in patients with severe bacteremia were similar to those in patients with nonsevere bacteremia, and levels in patients with STSS were similar to those in patients with NF. The data indicate that immunity to cell wall-attached proteins may play a role in the protection against severe invasive disease and that antibodies against GRAB may be of importance in the pathogenesis of STSS.
Similar articles
-
Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.J Infect Dis. 1999 Aug;180(2):410-8. doi: 10.1086/314872. J Infect Dis. 1999. PMID: 10395857
-
Human leukocyte antigen class II haplotypes that protect against or predispose to streptococcal toxic shock.Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S445-8. doi: 10.1086/431986. Clin Infect Dis. 2005. PMID: 16237645 Review.
-
IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection.Infect Immun. 2006 Jan;74(1):497-503. doi: 10.1128/IAI.74.1.497-503.2006. Infect Immun. 2006. PMID: 16369006 Free PMC article.
-
The flesh-eating bacterium: what's next?J Infect Dis. 1999 Mar;179 Suppl 2:S366-74. doi: 10.1086/513851. J Infect Dis. 1999. PMID: 10081509 Review.
-
Contribution of protein G-related alpha2-macroglobulin-binding protein to bacterial virulence in a mouse skin model of group A streptococcal infection.J Infect Dis. 2003 Jun 1;187(11):1694-703. doi: 10.1086/375029. Epub 2003 May 15. J Infect Dis. 2003. PMID: 12751026
Cited by
-
Streptococcal IdeS and its impact on immune response and inflammation.J Innate Immun. 2012;4(2):132-40. doi: 10.1159/000332940. Epub 2012 Jan 17. J Innate Immun. 2012. PMID: 22248585 Free PMC article. Review.
-
Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.J Immune Based Ther Vaccines. 2008 Oct 31;6:8. doi: 10.1186/1476-8518-6-8. J Immune Based Ther Vaccines. 2008. PMID: 18976486 Free PMC article.
-
Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase.Mol Pharmacol. 2013 Jun;83(6):1268-75. doi: 10.1124/mol.113.086470. Epub 2013 Apr 9. Mol Pharmacol. 2013. PMID: 23571414 Free PMC article.
-
Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS--A Novel Therapeutic Opportunity.PLoS One. 2015 Jul 15;10(7):e0132011. doi: 10.1371/journal.pone.0132011. eCollection 2015. PLoS One. 2015. PMID: 26177518 Free PMC article. Clinical Trial.
-
IdeS: a bacterial proteolytic enzyme with therapeutic potential.PLoS One. 2008 Feb 27;3(2):e1692. doi: 10.1371/journal.pone.0001692. PLoS One. 2008. PMID: 18301769 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical